Федеральные клинические рекомендации по ведению больных псориазом
|
Скачать 0.97 Mb.
|
|
Другие методы Санаторно-курортное лечение Санаторно-курортное лечение рекомендуется проводить в стационарную и регрессирующую стадии заболевания, а также в период ремиссии. Лечение сероводородными водами проводится на курортах Горячий Ключ, Ейск, Пятигорск, Сергиевские минеральные воды, Серноводск, Сочи, Мацеста, Хоста; кремнистыми водами — на курортах Горячинск, Талая; радоновыми водами — на курортах Белокуриха, Молоковка, Пятигорск. Критериями эффективности терапии являются сроки наступления клинического эффекта, длительность ремиссии, улучшение качества жизни пациента. Большое значение имеют уровень безопасности терапевтических средств, их переносимость и удобство применения. Госпитализация показана в следующих случаях:
В стационар дневного пребывания больные госпитализируются в случаях необходимости проведения инфузионной терапии (введения биологических генно-инженерных препаратов). Ошибки в терапии В терапии распространенных форм псориаза, особенно в стадию прогрессирования или в случаях торпидного течения заболевания, нередко используются глюкокортикостероидные препараты системного действия. Назначение глюкокортикостероидов длительными курсами может привести к генерализации кожного процесса с развитием пустулезного псориаза и/или эритродермии, торпидному течению заболевания. Применение системных глюкокортикостероидов показано при лечении псориатического артрита и в редких случаях тяжелого течения заболевания (генерализованный пустулезный псориаз, псориатическая эритродермия). В этих случаях оправдано назначение единичных инъекций (инфузий) кортикостероидов короткого действия с целью купирования остроты процесса. Список литературы 1. Ebell M, Siwek J, Weiss B, Woolf S, Susman J, Ewigman B, et al. Simplifying the language of evidence to improve patient care: strength of recommendation taxonomy (SORT); a patient-centered approach to grading evidence in medical literature. J Fam Pract 2004;53:111-20. 2. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826-50. 3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496-509. 4. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24. 5. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. 6. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53:573. 7. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7. 8. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9. 9. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42. 10. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 2003;48:805-21, quiz 22-4. 11. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain 2000;123:1102-11. 12. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201. 13. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9. 14. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35. 15. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. 16. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21. 17. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19: 225-30. 18. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56:629-34. 19. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34. 20. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses’ health study II. Arch Intern Med 2007;167:1670-5. 21. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications; report of an interdisciplinary conference and review. Br J Dermatol 2007; 157:649-55. 22. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-82. 23. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73. 24. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4. 25. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology 2006;212:123-7. 26. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50. 27. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. ArchDermatol 2010;146:891-5. 28. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3. 29. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7. 30. Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005;141:1580-4. 31. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: nurses’ health study II. Am J Med 2007;120:953-9. 32. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Karkkainen P. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990;300:780-3. 33. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-7. 34. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom. Br J Dermatol 2010;163:586-92. 35. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73. 36. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-5. 37. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207-11. 38. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008;128:1064-7. 39. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36. 40. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118:597-607. 41. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham- Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51. 42. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results froma randomized, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008;371:1675-84. 43. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebocontrolled trial (PHOENIX 1). Lancet 2008;371:1665-74. 44. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356: 580-92. 45. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87. 46. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15. 47. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44. 48. Ustekinumab [package insert]. Available from: URL:http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails. Accessed October 12, 2010. 49. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7. 50. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145: 937-42. 51. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60: 976-86. 52. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59. 53. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61: 451-85. 54. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62:114-35. 55. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007;143: 239-42. 56. Krueger GG, O’Reilly MA, Weidner M, Dromgoole SH, Killey FP. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol 1998;38: 186-90. 57. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975;111: 581-3. 58. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999;41:546-9. 59. Feldman SR. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol 2006; 24:229-30. 60. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205: 389-93. 61. Watsky KL, Freije L, Leneveu MC, Wenck HA, Leffell DJ. Waterin- oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992;50:383-6. 62. Rim JH, Jo SJ, Park JY, Park BD, Youn JI. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol 2005;30: 409-13. 63. Schmid-Ott G, Kuensebeck HW, Jaeger B, Werfel T, Frahm K, Ruitman J, et al. Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Derm Venereol 1999;79:443-7. 64. Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, et al. Treatment of intertriginous psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;60:120-4. 65. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010-1. 66. Zivkovich AH, Feldman SR. Are ointments better than other vehicles for corticosteroid treatment of psoriasis? J Drugs Dermatol 2009;8:570-2. 67. Maibach HI, Stoughton RB. Topical corticosteroids. Med Clin North Am 1973;57:1253-64. 68. Goon AT, Yosipovitch G, Chan YH, Goh CL. Barrier repair in chronic plaque-type psoriasis. Skin Res Technol 2004;10:10-3. 69. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005;141:601-6. 70. Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6. 71. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003;14:8-13. 72. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-7. 73. Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-11. 74. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000;22:1225-38. 75. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007;157:1005-12. 76. Kreuter A, Sommer A, Hyun J, Brautigam M, Brockmeyer NH, Altmeyer P, et al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43. 77. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006;55:607-13. 78. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008;59:27-33. 79. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-16. 80. Savary J, Ortonne JP, Aractingi S. The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments. J Eur Acad Dermatol Venereol 2005;19(Suppl):14-7. 81. Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicenter randomized controlled non-inferiority trial (PLUTO study). BMJ 2009;338:b1542. 82. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53. 83. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus- Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol 2008;7:796-804. 84. Miller DW, Feldman SR. Cost-effectiveness of moderate-tosevere psoriasis treatment. Expert Opin Pharmacother 2006; 7:157-67. 85. Sivanesan SP, Gattu S, Hong J, Chavez-Frazier A, Bandow GD, Malick F, et al. Randomized, double-blind, placebocontrolled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol 2009; 61:793-8. 86. Van Weelden H, Baart de la Faille H, Young E, van der Leun JC. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 1990;70:212-5. 87. Hofer A, Fink-Puches R, Kerl H, Wolf P. Comparison of phototherapy with near vs far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol 1998;138:96-100. 88. Tanew A, Radakovic-Fijan S, Schemper M, Honigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999;135:519-24. 89. Markham T, Rogers S, Collins P, Narrowband UV- B. (TL-01)phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325-8. 90. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41:728-32. 91. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836-42. 92. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen 1 ultraviolet A: a cohort study. J Invest Dermatol 2003;121: 252-8. 93. Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol 2005;44:1016-21. 94. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): a metaanalysis. Arch Dermatol 1998;134:1582-5. 95. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 2001;358:1042-5. 96. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using lowdose acitretin. Br J Dermatol 1999;140:656-60. 97. McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002;21:1201-5. 98. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998;134: 595-8. 99. Lindelof B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis: do the known risks now outweigh the benefits? Drug Saf 1999;20:289-97. 100. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl J Med 1997;336:1041-5. 101. Forman AB, Roenigk HH Jr, Caro WA, Magid ML. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989;125:515-9. 102. Chuang TY, Heinrich LA, Schultz MD, Reizner GT, Kumm RC, Cripps DJ. PUVA and skin cancer: a historical cohort study on 492 patients. J Am Acad Dermatol 1992;26:173-7. 103. Wolff K. Should PUVA be abandoned? N Engl J Med 1997;336: 1090-1. 104. Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol 2007;57:231-7. 105. Dawe RS. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. Br J Dermatol 2003;149:669-72. 106. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009;60:1024-31. 107. Spuls PI, Hadi S, Rivera L, Lebwohl M. Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat 2003;14(Suppl):21-5. 108. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009;22:56-60. 109. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8. 110. Allan SJ, Kavanagh GM, Herd RM, Savin JA. The effect ofinositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. Br J Dermatol 2004;150:966-9. 111. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, WangX, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9. 112. Gollnick HP. Oral retinoidseefficacy and toxicity in psoriasis. Br J Dermatol 1996;135(Suppl):6-17. 113. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Cyclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150(Suppl): 11-23. 114. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6. 115. Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-86. 116. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:947-55. 117. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31, e1-15. 118. Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumabrelated hepatotoxicity. Int J Immunopathol Pharmacol 2009; 22:547-9. 119. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 2005;366:1367-74. 120. Comte C, Guilhou JJ, Guillot B, Dereure O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology 2008;217:284-5. 121. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007;157:1076-8. 122. Fryrear RS II, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am AcadDermatol 2004;51:1026. 123. Wolfe F, Michaud K. Biologic treatment of rheumatoidarthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95. 124. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. 125. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51. 126. Clark L, Lebwohl M. The effect of weight on the efficacy ofbiologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58:443-6. 127. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010;63:448-56. 128. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41. 129. Rosenbach M, Hsu S, KormanNJ Lebwohl MG, Young M, Bebo BF Jr, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62:655-62. 130. Boyd AS, Menter A. Erythrodermic psoriasis: precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989;21:985-91. 131. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporin. Dermatology 1993;187(Suppl):30-7. 132. Morris LF, Harrod MJ, Menter MA, Silverman AK. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993;29:913-6. 133. Richetta AG, Maiani E, Carlomagno V, Carboni V, Mattozzi C, Giancristoforo S, et al. Treatment of erythrodermic psoriasis in HCV1 patient with adalimumab. Dermatol Ther 2009;22 (Suppl):S16-8. 134. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumor necrosis factor therapies. Br J Dermatol 2010;162:1144-6. 135. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008;159:931-5. 136. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexateeultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;7:758-62. 137. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006;54:1013-8. 138. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;6:46-51. 139. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644-50. 140. Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008;7:245-53. 141. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19:556-63. 142. Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143:1016-22. 143. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958;78:200-3. 144. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130: 204-10. 145. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37. 146. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-8. 147. Aithal GP. Dangerous liaisons: drug, host and the environment. J Hepatol 2007;46:995-8. 148. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicenter audit and health economic analysis. Br J Dermatol 2005;152:444-50. 149. Amor K, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010;63:925-46. 150. Ryan C, Amor K, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010;63:949-72. 151. Timonen P, Friend D, Abeywickrama K, Laburte C, von Graffenried B, Feutren G. Efficacy of low-dose cyclosporine A in psoriasis: results of dose-finding studies. Br J Dermatol 1990;122(Suppl):33-9. 152. Faerber L, Braeutigam M, Weidinger G, Mrowietz U, Christophers E, Schulze HJ, et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001;2:41-7. 153. Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999;26:141-9. 154. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997;133:711-5. 155. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 1992;27(Suppl):S29-33. 156. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995;131:1263-7. 157. Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003;139:1563-70. 158. Suarez-Farinas M, Shah KR. HaiderAS, Krueger JG, Lowes MA. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to alefacept. BMC Dermatol 2010;10:1. 159. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN. Antinuclear antibodies associate with loss of response to antitumor necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162:780-5. 160. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38: 1261-5. 161. Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumor necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010;62:1349-58. 162. Gordon K, Leonardi C, Lebwohl M. The ustekinumab safety experience in patients with moderate-to-severe psoriasis: results from pooled analyses of phase 2 and phase 3 clinical trial data. Poster P 1170 presented at European Academy of Dermatology and Venereology Annual Congress; October 7-11, 2009; Berlin, Germany. 163. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and cyclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006;31:520-4. 164. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporine for severe recalcitrant psoriasis. Br J Dermatol 1999; 141:279-82. 165. Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008;19: 22-6. 166. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005;24:37-45. 167. Yamauchi PS, Lowe NJ. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int J Dermatol 2008;47:202-4. 168. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. 169. Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev Clin Immunol 2008;4: 275-80. 170. Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol 2008;7:1089-93. 171. Robinson MR, Korman BD, Korman NJ. Combination immunosuppressive therapies: the promise and the peril. Arch Dermatol 2007;143:1053-7. 172. Griffiths CE, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long-term cyclosporin for psoriasis. Br J Dermatol 1989;120:253-60. 173. Gottlieb SL, Heftler NS, Gilleaudeau P, Johnson R, Vallat VP, Wolfe J, et al. Short-contact anthralin treatment augmentstherapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol 1995;33:637-45. 174. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68-74. 175. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001;26:480-3. 176. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. |
Похожие:
 |
Федеральные клинические рекомендации по ведению больных псориазом ... |
|
Федеральные клинические рекомендации по ведению больных педикулезом ... |
|
Федеральные клинические рекомендации по ведению больных пузырчаткой ... |
|
Федеральные клинические рекомендации по ведению больных сифилисом ... |
|
Федеральные клинические рекомендации по ведению больных микроспорией ... |
|
Федеральные клинические рекомендации по ведению больных педикулезом ... |
|
Федеральные клинические рекомендации по ведению больных трихофитией ... |
|
Федеральные клинические рекомендации по ведению больных себорейным дерматитом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Себорейный... |
|
Федеральные клинические рекомендации по ведению больных себорейным дерматитом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Себорейный... |
|
Федеральные клинические рекомендации по ведению больных атопическим дерматитом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Атопический... |
|
Федеральные клинические рекомендации по ведению больных периоральным дерматитом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю «Дерматовенерология», раздел «Периоральный... |
|
Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Урогенитальный... |
|
Федеральные клинические рекомендации по ведению больных фототоксическими и Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Фототоксические... |
|
Федеральные клинические рекомендации по ведению больных атопическим дерматитом Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Атопический... |
|
Федеральные клинические рекомендации по ведению больных разноцветным лишаем Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Разноцветный... |
|
Федеральные клинические рекомендации по ведению больных локализованной склеродермией Персональный состав рабочей группы по подготовке федеральных клинических рекомендаций по профилю "Дерматовенерология", раздел «Локализованная... |